XML 40 R29.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenue (Tables) | 9 Months Ended
--- | ---
Jul. 31, 2019
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended July 31, 2019
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |
Americas | $ | 160 |  |  | $ | 138 |  |  | $ | 167 |  |  | $ | 465 |
Europe | 118 |  |  | 91 |  |  | 130 |  |  | 339 |
Asia Pacific | 266 |  |  | 34 |  |  | 170 |  |  | 470 |
Total | $ | 544 |  |  | $ | 263 |  |  | $ | 467 |  |  | $ | 1,274 |
| Nine Months Ended July 31, 2019
| Life Sciences and Applied Markets |  | Diagnostics and Genomics |  | Agilent CrossLab |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |
Americas | $ | 473 |  |  | $ | 367 |  |  | $ | 491 |  |  | $ | 1,331 |
Europe | 407 |  |  | 279 |  |  | 390 |  |  | 1,076 |
Asia Pacific | 800 |  |  | 106 |  |  | 483 |  |  | 1,389 |
Total | $ | 1,680 |  |  | $ | 752 |  |  | $ | 1,364 |  |  | $ | 3,796 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Nine Months Ended
| July 31, 2019 |  | July 31, 2019
| (in millions)
Revenue by End Markets |  |  |
Pharmaceutical and Biotechnology | $ | 416 |  |  | $ | 1,178 |
Chemical and Energy | 291 |  |  | 899 |
Diagnostics and Clinical | 198 |  |  | 578 |
Food | 116 |  |  | 359 |
Academia and Government | 103 |  |  | 333 |
Environmental and Forensics | 150 |  |  | 449 |
Total | $ | 1,274 |  |  | $ | 3,796 |
Revenue by Type |  |  |
Instrumentation | $ | 505 |  |  | $ | 1,563 |
Non-instrumentation and other | 769 |  |  | 2,233 |
Total | $ | 1,274 |  |  | $ | 3,796 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2019:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2018 |  | $ | 367 |
Impact of adoption of new revenue recognition guidance |  | (11 | )
Net revenue deferred in the period |  | 263 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (230 | )
Change in deferrals from customer cash advances, net of revenue recognized |  | — |
Contract liabilities acquired in business combinations |  | 2 |
Currency translation and other adjustments |  | — |
Ending balance as of July 31, 2019 |  | $ | 391 |

X
- Definition Tabular disclosure of contract balances and changes in contract balances. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration